A

Advaxis Inc
F:FAD2

Watchlist Manager
Advaxis Inc
F:FAD2
Watchlist
Price: 0.0849 EUR -0.35% Market Closed
Market Cap: 12.4m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

FAD2 price has not been updated for more than 11 months. This may indicate that the stock has been delisted.
FAD2 doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of FAD2.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FAD2 Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

1 108.2
P/S
P/S
Price to Sales
1 108.2
vs History
11
vs Industry
4
Median 3Y
1 027.7
Median 5Y
111.6
Industry
7.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0.3
Median 5Y
-0.7
Industry
24.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.8
Industry
21.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.8
Industry
22.9
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
0.4
Industry
3
More Details
1 333.5
EV/S
EV/S
Enterprise Value to Sales
1 333.5
vs History
1
vs Industry
3
Median 3Y
1 239.9
Median 5Y
52.3
Industry
8.2
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.5
Industry
5.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-0.4
Median 5Y
-0.5
Industry
5.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.6
Industry
6.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.6
Industry
4.3
More Details
3.3
EV/IC
EV/IC
Enterprise Value to IC
3.3
vs History
16
vs Industry
39
Median 3Y
3.1
Median 5Y
3
Industry
5.3
More Details

Multiples Across Competitors

FAD2 Competitors Multiples
Advaxis Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Advaxis Inc
F:FAD2
12.4m EUR 1 108.2 -0.3 -0.5 -0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 055 913.5 -161 862.7 -196 553 -194 310.1
US
Abbvie Inc
NYSE:ABBV
365.1B USD 6.3 98.1 16.1 23.4
US
Amgen Inc
NASDAQ:AMGN
159.5B USD 4.6 24.1 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
147B USD 5.1 23.3 10.8 14.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 068.6 -527.9 -574.8 -559.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
100.7B USD 8.8 27.7 20.4 21.3
AU
CSL Ltd
ASX:CSL
130.9B AUD 5.6 31 19 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.8B USD 4.3 13.9 12.5 14
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
58.8B USD 23.9 -184.3 -460.6 -316.2
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.1 -65.9 -59.4
P/S Multiple
Revenue Growth P/S to Growth
US
A
Advaxis Inc
F:FAD2
Average P/S: 3 096 288.1
1 108.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 055 913.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
E
Epizyme Inc
F:EPE
2 068.6
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.8
10%
0.9
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
4%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
23.9
31%
0.8
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
P/E Multiple
Earnings Growth PEG
US
A
Advaxis Inc
F:FAD2
Average P/E: 36.3
Negative Multiple: -0.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 862.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
98.1
88%
1.1
US
Amgen Inc
NASDAQ:AMGN
24.1
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
N/A N/A
AU
CSL Ltd
ASX:CSL
31
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
7%
2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -184.3 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Advaxis Inc
F:FAD2
Average EV/EBITDA: 16.3
Negative Multiple: -0.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 553 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.4
17%
1.2
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -460.6 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Advaxis Inc
F:FAD2
Average EV/EBIT: 19.4
Negative Multiple: -0.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 310.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.9
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.3
17%
1.3
AU
CSL Ltd
ASX:CSL
23.7
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -316.2 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A

See Also

Summary
FAD2 intrinsic value, competitors valuation, and company profile.
DCF Valuation
FAD2 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FAD2 stock valuation using valuation multiples.
Wall Street Estimates
FAD2 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FAD2 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 275,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.